Neuspera Medical this week announced its ultra-miniaturized neurostimulator system received FDA clearance.
The Neuspera system is a micro-implant that delivers neurostimulation therapy through a wireless platform, including a wearable transmitter and iPad-based clinician programmer. The company designed the system to provide peripheral nerve stimulation (PNS) in an ultra-miniaturized option to allow for a better patient experience and greater procedural flexibility.
Neuspera’s system is 75x smaller than the most miniature commercial implantable pulse generator, according to the company. It gives physicians the opportunity for deeper anatomical targets.
“We look forward to bringing this innovative technology to physicians and patients in the U.S.,” CEO Steffen Hovard said in a news release. “The Neuspera ultra-miniaturized system has the potential to revolutionize the way physicians treat patients battling chronic pain while restoring patients’ health and quality of life.”
The company noted that the growth of PNS technology and treatment has been significant in recent years. The PNS space has seen a growth in implantable device technology and an increasing number of clinical studies focused on developing new therapies.
